Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.
作者信息
Vlachogiannakos J, Tang A K, Patch D, Burroughs A K
机构信息
Liver Transplantation and Hepatobiliary Medicine Royal Free Hospital, London, UK.
出版信息
Gut. 2001 Aug;49(2):303-8. doi: 10.1136/gut.49.2.303.
Abstract
摘要
相似文献
1
Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.
Gut. 2001 Aug;49(2):303-8. doi: 10.1136/gut.49.2.303.
2
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Presse Med. 2002 Nov 9;31(36):1714-20.
3
[Angiotensin II receptor antagonists and portal hypertension].
Gastroenterol Clin Biol. 2002 Mar;26(3):254-5.
4
Which drug for treatment of hypertension?
Lancet. 1999 Feb 20;353(9153):604-5. doi: 10.1016/S0140-6736(98)00361-4.
5
Antagonists of the angiotensin II type 1 receptor: an approach to control vascular disease beyond blood pressure lowering?
J Hypertens. 2002 Feb;20(2):183-6. doi: 10.1097/00004872-200202000-00006.
6
Angiotensin receptor blockade and portal hypertension: paradise gained and paradise lost.
Gastroenterology. 2001 Aug;121(2):487-90. doi: 10.1053/gast.2001.26770.
7
[Angiotensin-II receptor blockers in the treatment of arterial hypertension].
Eksp Klin Farmakol. 1996 Sep-Oct;59(5):76-80.
8
Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade.
Am J Cardiol. 2002 Sep 15;90(6):662-3. doi: 10.1016/s0002-9149(02)02580-8.
9
The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.
J Gastrointestin Liver Dis. 2006 Dec;15(4):337-42.
10
[Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
Clin Ter. 2001 Mar-Apr;152(2):77-8.
引用本文的文献
1
The Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes.
Am J Gastroenterol. 2025 May 1;120(5):1057-1065. doi: 10.14309/ajg.0000000000002976. Epub 2024 Jul 25.
2
Clinical Presentation, Pathological Spectrum, and Outcomes of Alcoholic Cirrhosis-Related Immunoglobulin A Nephropathy.
Kidney Int Rep. 2024 Feb 16;9(5):1369-1378. doi: 10.1016/j.ekir.2024.02.1397. eCollection 2024 May.
3
Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy.
World J Gastroenterol. 2023 Jan 7;29(1):61-74. doi: 10.3748/wjg.v29.i1.61.
4
Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
J Gastroenterol Hepatol. 2022 May;37(5):795-811. doi: 10.1111/jgh.15787. Epub 2022 Feb 8.
5
SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites.
Clin Liver Dis (Hoboken). 2018 Jul 26;11(6):141-144. doi: 10.1002/cld.714. eCollection 2018 Jun.
6
A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.
Pharmacol Rev. 2012 Dec 20;65(1):1-46. doi: 10.1124/pr.112.006809. Print 2013 Jan.
7
Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection.
AIDS Res Treat. 2012;2012:978790. doi: 10.1155/2012/978790. Epub 2012 Nov 1.
8
Quantitative modeling of the physiology of ascites in portal hypertension.
BMC Gastroenterol. 2012 Mar 27;12:26. doi: 10.1186/1471-230X-12-26.
9
Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.
J Gastroenterol Hepatol. 2008 Sep;23(9):1327-38. doi: 10.1111/j.1440-1746.2008.05461.x. Epub 2008 Jun 28.
10
Nonalcoholic fatty liver disease as a component of the metabolic syndrome.
Curr Gastroenterol Rep. 2008 Feb;10(1):73-80. doi: 10.1007/s11894-008-0012-0.
本文引用的文献
1
Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man.
JAMA. 1960 Sep 17;174:234-40. doi: 10.1001/jama.1960.03030030014003.
2
Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis.
Aliment Pharmacol Ther. 2000 Jul;14(7):851-60. doi: 10.1046/j.1365-2036.2000.00778.x.
3
Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy.
Gastroenterology. 2000 Jun;118(6):1261-5. doi: 10.1016/s0016-5085(00)70379-9.
4
Angiotensin II induces contraction and proliferation of human hepatic stellate cells.
Gastroenterology. 2000 Jun;118(6):1149-56. doi: 10.1016/s0016-5085(00)70368-4.
5
Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis.
Gastroenterology. 2000 Mar;118(3):565-72. doi: 10.1016/s0016-5085(00)70263-0.
6
Angiotensin II receptor antagonists.
Lancet. 2000 Feb 19;355(9204):637-45. doi: 10.1016/s0140-6736(99)10365-9.
7
Hepatic stellate cells and the regulation of liver inflammation.
J Hepatol. 1999 Dec;31(6):1120-30. doi: 10.1016/s0168-8278(99)80327-4.
8
Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis.
Gut. 2000 Jan;46(1):114-20. doi: 10.1136/gut.46.1.114.
9
Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution.
Gastroenterology. 1999 Sep;117(3):740-2. doi: 10.1016/s0016-5085(99)70472-5.
10
Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
Hepatology. 1999 Feb;29(2):334-9. doi: 10.1002/hep.510290203.
Zotero 插件